Stepan Reports Fourth Quarter and Full Year 2025 Results
Fourth Quarter 2025 Highlights
- Reported net income was
$5.0 million , up 49% versus the prior year. Adjusted net income(1) was a$0.5 million loss, down 119% versus the prior year, largely due to higher interest expense, resulting from lower capitalized interest income recognition due to thePasadena, TX site start-up, a less favorable effective tax rate and lower Surfactant earnings. - EBITDA(2) was
$43.3 million , up 21% versus the prior year. Adjusted EBITDA(2) was$33.8 million , down 3% year-over-year. - Global sales volume was down 3% year-over-year. Global sales volume, excluding the impact of
the Philippines asset divestiture, was flat year-over-year. - Cash from Operations was
$60.0 million during the quarter. Free cash flow(3) for the quarter was$25.4 million , driven by a reduction in working capital. - Pre-tax earnings include
$6.2 million of goodwill impairment expense related to the Company's Mexican reporting unit and$15.9 million of gains related to the previously announcedPhilippines andLake Providence, LA asset divestitures.
Full Year 2025 Highlights
- Reported net income was
$46.9 million , down 7% versus the prior year. Adjusted net income(1) was$41.7 million , down 17% versus the prior year. - EBITDA(2) was
$208.0 million and Adjusted EBITDA(2) was$198.9 million , up 11% and 6%, respectively, year-over-year. - Global sales volume was up 1% year-over-year. Global sales volume, excluding the impact of
the Philippines asset divestiture, was up 2% year-over-year.
"2025 was a transformational year for Stepan as we divested two plant sites and completed preliminary work that has positioned us to further optimize our footprint and asset base in 2026. Despite many challenges in 2025, we delivered growth in several of our core businesses, advanced several strategic initiatives and have an operational plan in place to accelerate profitable growth moving forward. Full year adjusted EBITDA grew 6% versus prior year despite a significant increase in oleochemical raw material costs and start-up expenses at our
Financial Summary
|
|
|
Three Months Ended |
|
|
Twelve Months Ended |
|
||||||||||||||||||
|
($ in thousands, except per share data) |
|
2025 |
|
|
2024 |
|
|
% |
|
|
2025 |
|
|
2024 |
|
|
% |
|
||||||
|
|
|
$ |
553,886 |
|
|
$ |
525,609 |
|
|
|
5 |
% |
|
$ |
2,332,114 |
|
|
$ |
2,180,274 |
|
|
|
7 |
% |
|
Operating Income |
|
$ |
10,502 |
|
|
$ |
7,695 |
|
|
|
36 |
% |
|
$ |
78,549 |
|
|
$ |
70,480 |
|
|
|
11 |
% |
|
Net Income |
|
$ |
5,004 |
|
|
$ |
3,350 |
|
|
|
49 |
% |
|
$ |
46,895 |
|
|
$ |
50,370 |
|
|
|
(7) |
% |
|
Earnings per Diluted Share |
|
$ |
0.22 |
|
|
$ |
0.15 |
|
|
|
47 |
% |
|
$ |
2.05 |
|
|
$ |
2.20 |
|
|
|
(7) |
% |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||||
|
Adjusted Net Income * |
|
$ |
(531) |
|
|
$ |
2,757 |
|
|
|
(119) |
% |
|
$ |
41,680 |
|
|
$ |
50,470 |
|
|
|
(17) |
% |
|
Adjusted Earnings per |
|
$ |
(0.02) |
|
|
$ |
0.12 |
|
|
|
(117) |
% |
|
$ |
1.82 |
|
|
$ |
2.20 |
|
|
|
(17) |
% |
|
|
|
|
* See Table II for reconciliations of non-GAAP adjusted net income and adjusted earnings per diluted share. |
|
Percentage Change in
Net sales in the fourth quarter of 2025 increased 5% year-over-year. This increase reflects higher selling prices, that were mainly attributable to the pass-through of higher raw material costs and more favorable product mix, and the favorable impact of foreign currency translation. A 3% decline in sales volume partially offset the above.
|
|
|
Three Months Ended |
|
|
Twelve Months Ended |
|
||
|
Volume |
|
|
(3) |
% |
|
|
1 |
% |
|
Selling Price & Mix |
|
|
5 |
% |
|
|
6 |
% |
|
Foreign Translation |
|
|
3 |
% |
|
|
(—) |
% |
|
Total |
|
|
5 |
% |
|
|
7 |
% |
Segment Results
|
|
|
Three Months Ended |
|
|
Twelve Months Ended |
|
||||||||||||||||||
|
($ in thousands) |
|
2025 |
|
|
2024 |
|
|
% |
|
|
2025 |
|
|
2024 |
|
|
% |
|
||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||||
|
Surfactants |
|
$ |
401,832 |
|
|
$ |
378,776 |
|
|
|
6 |
% |
|
$ |
1,665,983 |
|
|
$ |
1,532,115 |
|
|
|
9 |
% |
|
Polymers |
|
$ |
131,682 |
|
|
$ |
129,844 |
|
|
|
1 |
% |
|
$ |
584,477 |
|
|
$ |
584,905 |
|
|
|
(0) |
% |
|
Specialty Products |
|
$ |
20,372 |
|
|
$ |
16,989 |
|
|
|
20 |
% |
|
$ |
81,654 |
|
|
$ |
63,254 |
|
|
|
29 |
% |
|
Total |
|
$ |
553,886 |
|
|
$ |
525,609 |
|
|
|
5 |
% |
|
$ |
2,332,114 |
|
|
$ |
2,180,274 |
|
|
|
7 |
% |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Three Months Ended |
|
|
Twelve Months Ended |
|
||||||||||||||||||
|
($ in thousands, all amounts pre-tax) |
|
2025 |
|
|
2024 |
|
|
% |
|
|
2025 |
|
|
2024 |
|
|
% |
|
||||||
|
Operating Income |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||||
|
Surfactants |
|
$ |
9,343 |
|
|
$ |
16,173 |
|
|
|
(42) |
% |
|
$ |
67,358 |
|
|
$ |
85,618 |
|
|
|
(21) |
% |
|
Polymers |
|
$ |
3,984 |
|
|
$ |
3,396 |
|
|
|
17 |
% |
|
$ |
43,265 |
|
|
$ |
40,623 |
|
|
|
7 |
% |
|
Specialty Products |
|
$ |
5,240 |
|
|
$ |
5,594 |
|
|
|
(6) |
% |
|
$ |
25,640 |
|
|
$ |
20,908 |
|
|
|
23 |
% |
|
Total Segment |
|
$ |
18,567 |
|
|
$ |
25,163 |
|
|
|
(26) |
% |
|
$ |
136,263 |
|
|
$ |
147,149 |
|
|
|
(7) |
% |
|
Corporate Expenses |
|
$ |
(8,065) |
|
|
$ |
(17,468) |
|
|
|
(54) |
% |
|
$ |
(57,714) |
|
|
$ |
(76,669) |
|
|
|
(25) |
% |
|
Consolidated |
|
$ |
10,502 |
|
|
$ |
7,695 |
|
|
|
36 |
% |
|
$ |
78,549 |
|
|
$ |
70,480 |
|
|
|
11 |
% |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Three Months Ended |
|
|
Year Ended |
|
||||||||||||||||||
|
($ in millions) |
|
2025 |
|
|
2024 |
|
|
% |
|
|
2025 |
|
|
2024 |
|
|
% |
|
||||||
|
EBITDA |
|
$ |
43.3 |
|
|
$ |
35.8 |
|
|
|
21 |
% |
|
$ |
208.0 |
|
|
$ |
186.9 |
|
|
|
11 |
% |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||||
|
Adjusted EBITDA |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||||
|
Surfactants |
|
$ |
32.1 |
|
|
$ |
34.7 |
|
|
|
(7) |
% |
|
$ |
153.0 |
|
|
$ |
157.6 |
|
|
|
(3) |
% |
|
Polymers |
|
$ |
12.4 |
|
|
$ |
11.4 |
|
|
|
9 |
% |
|
$ |
76.4 |
|
|
$ |
73.0 |
|
|
|
5 |
% |
|
Specialty Products |
|
$ |
6.7 |
|
|
$ |
7.1 |
|
|
|
(6) |
% |
|
$ |
31.5 |
|
|
$ |
26.9 |
|
|
|
17 |
% |
|
Unallocated Corporate |
|
$ |
(17.4) |
|
|
$ |
(18.2) |
|
|
|
(4) |
% |
|
$ |
(62.0) |
|
|
$ |
(70.5) |
|
|
|
(12) |
% |
|
Consolidated Adjusted EBITDA |
|
$ |
33.8 |
|
|
$ |
35.0 |
|
|
|
(3) |
% |
|
$ |
198.9 |
|
|
$ |
187.0 |
|
|
|
6 |
% |
Consolidated adjusted EBITDA(2) decreased
- Surfactant net sales were
$401.8 million for the quarter, a 6% increase versus the prior year. Selling prices were up 10% primarily due to pass through of higher raw material costs, improved product and customer mix, along with pricing actions. Sales volume declined 7% year-over-year primarily due to lower demand within the commodity Laundry & Cleaning end markets, lower demand from our distribution partners and lower volume inthe Philippines due to the asset divestiture. Excluding the impact ofthe Philippines , organic volume declined 3%. These declines were partially offset by double digit growth within the Industrial Cleaning end markets and year-over-year growth within the Agricultural and Oilfield end markets. Foreign currency translation positively impacted net sales by 3%. Surfactant adjusted EBITDA(2) for the quarter decreased$2.6 million , or 7%, versus the prior year. This decrease was primarily due to the 7% decrease in sales volume. - Polymer net sales were
$131.7 million for the quarter, a 1% increase versus the prior year. Selling prices decreased 12%, primarily due to the pass-through of lower raw material costs and competitive pressures. Sales volume increased 11% in the quarter. North American Rigid and commodity Phthalic Anhydride sales volume was up double digits year-over-year. Foreign currency translation positively impacted net sales by 2% during the quarter. Polymer adjusted EBITDA(2) increased$1.0 million , or 9%, versus the prior year primarily due to the 11% increase in sales volume. - Specialty Products net sales were
$20.4 million for the quarter, a 20% increase versus the prior year, primarily due to higher sales volume. Specialty Products adjusted EBITDA(2) decreased$0.4 million , or 6%. The decrease in adjusted EBITDA(2) was primarily due to lower margins resulting from order timing fluctuations within the pharmaceutical business.
Income Taxes
The Company's effective tax rate was 21.7% in 2025 versus 16.7% in 2024. This increase was primarily attributable to the non-recurrence of favorable deferred tax adjustments recognized in 2024.
Outlook
"As we look forward to 2026, we remain focused on delivering superior shareholder returns with a balanced approach between top line growth and productivity cost out efforts. Today we announced Project Catalyst, which is a comprehensive plan designed to further optimize our asset base and create a more productive and agile organization to enable growth. Project Catalyst is expected to deliver approximately
Notes
|
(1) Adjusted net income and adjusted earnings per share are non-GAAP measures which exclude deferred compensation income/expense, certain environmental remediation-related costs as well as other significant and infrequent/non-recurring items. See Table II for reconciliations of non-GAAP adjusted net income and adjusted earnings per diluted share. |
|
|
|
(2) EBITDA and adjusted EBITDA are non-GAAP measures. See Table VI for calculations and GAAP reconciliations of EBITDA and adjusted EBITDA. |
|
|
|
(3) Free cash flow is a non-GAAP measure and reflects cash generated from operations minus capital expenditures. Cash generated from operations was |
Conference Call
Supporting Slides
Slides supporting this press release will be made available at www.stepan.com through the Investors/Presentations page at approximately the same time as this press release is issued.
Corporate Profile
Headquartered in
The Company's common stock is traded on the
More information about Stepan's sustainability program can be found on the Sustainability page at www.stepan.com.
Certain information in this news release consists of forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These statements include statements about
There are a number of risks, uncertainties and other important factors, many of which are beyond
These forward-looking statements are made only as of the date hereof, and
* * * * *
Tables follow
Table I
|
For the Three and Twelve Months Ended (Unaudited – in 000's, except per share data) |
||||||||||||||||
|
|
||||||||||||||||
|
|
|
Three Months Ended |
|
|
Twelve Months Ended |
|
||||||||||
|
|
|
2025 |
|
|
2024 |
|
|
2025 |
|
|
2024 |
|
||||
|
|
|
$ |
553,886 |
|
|
$ |
525,609 |
|
|
$ |
2,332,114 |
|
|
$ |
2,180,274 |
|
|
Cost of Sales |
|
|
502,369 |
|
|
|
468,913 |
|
|
|
2,062,226 |
|
|
|
1,908,060 |
|
|
Gross Profit |
|
|
51,517 |
|
|
|
56,696 |
|
|
|
269,888 |
|
|
|
272,214 |
|
|
Operating Expenses: |
|
|
|
|
|
|
|
|
|
|
|
|
||||
|
Selling |
|
|
10,703 |
|
|
|
11,018 |
|
|
|
48,767 |
|
|
|
45,628 |
|
|
Administrative |
|
|
23,710 |
|
|
|
24,764 |
|
|
|
90,789 |
|
|
|
98,277 |
|
|
|
|
|
15,703 |
|
|
|
13,793 |
|
|
|
59,278 |
|
|
|
55,674 |
|
|
Deferred Compensation Expense |
|
|
549 |
|
|
|
(574) |
|
|
|
2,155 |
|
|
|
2,155 |
|
|
|
|
|
50,665 |
|
|
|
49,001 |
|
|
|
200,989 |
|
|
|
201,734 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||
|
Goodwill Impairment |
|
|
6,245 |
|
|
|
- |
|
|
|
6,245 |
|
|
|
- |
|
|
Gain on sale of assets |
|
|
(15,895) |
|
|
|
- |
|
|
|
(15,895) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||
|
Operating Income |
|
|
10,502 |
|
|
|
7,695 |
|
|
|
78,549 |
|
|
|
70,480 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||
|
Other Income (Expense): |
|
|
|
|
|
|
|
|
|
|
|
|
||||
|
Interest, Net |
|
|
(5,689) |
|
|
|
(4,829) |
|
|
|
(22,115) |
|
|
|
(14,182) |
|
|
Other, Net |
|
|
126 |
|
|
|
(410) |
|
|
|
3,470 |
|
|
|
4,141 |
|
|
|
|
|
(5,563) |
|
|
|
(5,239) |
|
|
|
(18,645) |
|
|
|
(10,041) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||
|
Income Before Provision for Income Taxes |
|
|
4,939 |
|
|
|
2,456 |
|
|
|
59,904 |
|
|
|
60,439 |
|
|
Provision for Income Taxes |
|
|
(65) |
|
|
|
(894) |
|
|
|
13,009 |
|
|
|
10,069 |
|
|
Net Income |
|
|
5,004 |
|
|
|
3,350 |
|
|
|
46,895 |
|
|
|
50,370 |
|
|
Net Income Per Common Share |
|
|
|
|
|
|
|
|
|
|
|
|
||||
|
Basic |
|
$ |
0.22 |
|
|
$ |
0.15 |
|
|
$ |
2.05 |
|
|
$ |
2.21 |
|
|
Diluted |
|
$ |
0.22 |
|
|
$ |
0.15 |
|
|
$ |
2.05 |
|
|
$ |
2.20 |
|
|
Shares Used to Compute Net Income Per |
|
|
|
|
|
|
|
|
|
|
|
|
||||
|
Basic |
|
|
22,878 |
|
|
|
22,841 |
|
|
|
22,872 |
|
|
|
22,832 |
|
|
Diluted |
|
|
22,891 |
|
|
|
22,912 |
|
|
|
22,890 |
|
|
|
22,931 |
|
Table II
|
Reconciliation of Non-GAAP Net Income and Earnings per Diluted Share* |
||||||||||||||||||||||||||||||||
|
|
||||||||||||||||||||||||||||||||
|
|
|
Three Months Ended |
|
|
Twelve Months Ended |
|
||||||||||||||||||||||||||
|
($ in thousands, except per share amounts) |
|
2025 |
|
|
EPS |
|
|
2024 |
|
|
EPS |
|
|
2025 |
|
|
EPS |
|
|
2024 |
|
|
EPS |
|
||||||||
|
Net Income Reported |
|
$ |
5,004 |
|
|
$ |
0.22 |
|
|
$ |
3,350 |
|
|
$ |
0.15 |
|
|
$ |
46,895 |
|
|
$ |
2.05 |
|
|
$ |
50,370 |
|
|
$ |
2.20 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||||||
|
Deferred Compensation (Income) |
|
$ |
76 |
|
|
$ |
0.01 |
|
|
$ |
(762) |
|
|
$ |
(0.03) |
|
|
$ |
(473) |
|
|
$ |
(0.02) |
|
|
$ |
(1,805) |
|
|
$ |
(0.08) |
|
|
Environmental Remediation |
|
$ |
65 |
|
|
$ |
0.00 |
|
|
$ |
169 |
|
|
$ |
- |
|
|
$ |
934 |
|
|
$ |
0.04 |
|
|
$ |
1,905 |
|
|
$ |
0.08 |
|
|
Goodwill Impairment |
|
$ |
6,245 |
|
|
$ |
0.27 |
|
|
$ |
- |
|
|
$ |
- |
|
|
$ |
6,245 |
|
|
$ |
0.27 |
|
|
$ |
- |
|
|
$ |
- |
|
|
Gain on Sale of Assets |
|
$ |
(11,921) |
|
|
$ |
(0.52) |
|
|
$ |
- |
|
|
$ |
- |
|
|
$ |
(11,921) |
|
|
$ |
(0.52) |
|
|
$ |
- |
|
|
$ |
- |
|
|
Adjusted Net Income |
|
$ |
(531) |
|
|
$ |
(0.02) |
|
|
$ |
2,757 |
|
|
$ |
0.12 |
|
|
$ |
41,680 |
|
|
$ |
1.82 |
|
|
$ |
50,470 |
|
|
$ |
2.20 |
|
|
|
|
* All amounts in this table are presented after-tax |
The Company believes that certain non-GAAP measures, in conjunction with comparable GAAP measures, are useful for evaluating the Company's operating performance and financial condition. The Company uses this non-GAAP information as an indicator of business performance and evaluates management's effectiveness with specific reference to these indicators. Management believes that these non-GAAP financial measures provide useful supplemental information because they exclude non-operational items that affect comparability between years. These measures should be considered in addition to, not as substitutes for or superior to, measures of financial performance prepared in accordance with GAAP and may differ from similarly titled measures presented by other companies. The Company's Annual Report on Form 10-K for the year ended
Summary of Fourth Quarter 2025 Adjusted Net Income Items
Adjusted net income excludes non-operational deferred compensation income/expense, certain environmental remediation costs and other significant and infrequent or non-recurring items.
-
Deferred Compensation: The fourth quarter of 2025 reported net income includes
$0.1 million of after-tax expense versus$0.8 million of after-tax income in the prior year. -
Environmental Remediation: The fourth quarter of 2025 reported net income includes
$0.1 million of after-tax expense versus$0.2 million of after-tax expense in the prior year. -
Goodwill Impairment: The fourth quarter of 2025 reported net income includes
$6.2 million of after-tax expense related to a goodwill impairment charge taken for the Company's Mexican reporting unit. There were no impairment charges taken in the prior year. -
Gain on Sale of Assets: The fourth quarter of 2025 reported net income includes
$11.9 million of after-tax income related to the previously announcedPhilippines andLake Providence, LA asset sales.
Table III
Reconciliation of Pre-Tax to After-Tax Adjustments
Management uses the non-GAAP adjusted net income metric to evaluate the Company's operating performance. Management excludes the items listed in the table below because they are non-operational items. The cumulative tax effect was calculated using the statutory tax rates for the jurisdictions in which the transactions occurred.
|
|
|
Three Months Ended |
|
|
Twelve Months Ended |
|
||||||||||||||||||||||||||
|
($ in thousands, except per share amounts) |
|
2025 |
|
|
EPS |
|
|
2024 |
|
|
EPS |
|
|
2025 |
|
|
EPS |
|
|
2024 |
|
|
EPS |
|
||||||||
|
Pre-Tax Adjustments |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||||||
|
Deferred Compensation (Income) |
|
$ |
101 |
|
|
|
|
|
$ |
(1,016) |
|
|
|
|
|
$ |
(631) |
|
|
|
|
|
$ |
(2,406) |
|
|
|
|
||||
|
Environmental Remediation Expense |
|
$ |
87 |
|
|
|
|
|
$ |
225 |
|
|
|
|
|
$ |
1,245 |
|
|
|
|
|
$ |
2,540 |
|
|
|
|
||||
|
Goodwill Impairment |
|
$ |
6,245 |
|
|
|
|
|
$ |
- |
|
|
|
|
|
$ |
6,245 |
|
|
|
|
|
$ |
- |
|
|
|
|
||||
|
Gain on Sale of Assets |
|
$ |
(15,895) |
|
|
|
|
|
$ |
- |
|
|
|
|
|
$ |
(15,895) |
|
|
|
|
|
$ |
- |
|
|
|
|
||||
|
Total Pre-Tax Adjustments |
|
$ |
(9,462) |
|
|
|
|
|
$ |
(791) |
|
|
|
|
|
$ |
(9,036) |
|
|
|
|
|
$ |
134 |
|
|
|
|
||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||||||
|
Cumulative Tax Effect on Adjustments |
|
$ |
3,927 |
|
|
|
|
|
$ |
198 |
|
|
|
|
|
$ |
3,821 |
|
|
|
|
|
$ |
(34) |
|
|
|
|
||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||||||
|
After-Tax Adjustments |
|
$ |
(5,535) |
|
|
$ |
(0.24) |
|
|
$ |
(593) |
|
|
$ |
(0.03) |
|
|
$ |
(5,215) |
|
|
$ |
(0.23) |
|
|
$ |
100 |
|
|
$ |
0.00 |
|
Table IV
Deferred Compensation Plans
The full effect of the deferred compensation plans on quarterly pre-tax income was
|
|
|
2025 |
|
|
2024 |
|
||||||||||||||||||||||||||
|
|
|
12/31 |
|
|
9/30 |
|
|
6/30 |
|
|
3/31 |
|
|
12/31 |
|
|
9/30 |
|
|
6/30 |
|
|
3/31 |
|
||||||||
|
|
|
$ |
47.36 |
|
|
$ |
47.70 |
|
|
$ |
54.58 |
|
|
$ |
55.04 |
|
|
$ |
64.70 |
|
|
$ |
77.25 |
|
|
$ |
83.96 |
|
|
$ |
90.04 |
|
|
|
|
Three Months Ended |
|
|
Twelve Months Ended |
|
||||||||||
|
($ in thousands) |
|
2025 |
|
|
2024 |
|
|
2025 |
|
|
2024 |
|
||||
|
Deferred Compensation |
|
|
|
|
|
|
|
|
|
|
|
|
||||
|
Operating Income (Expense) |
|
$ |
(549) |
|
|
$ |
574 |
|
|
$ |
(2,155) |
|
|
$ |
(2,155) |
|
|
Other, net – Mutual Fund Gain (Loss) |
|
|
448 |
|
|
|
442 |
|
|
|
2,786 |
|
|
|
4,561 |
|
|
Total Pre-Tax |
|
$ |
(101) |
|
|
$ |
1,016 |
|
|
$ |
631 |
|
|
$ |
2,406 |
|
|
Total After-Tax |
|
$ |
(76) |
|
|
$ |
762 |
|
|
$ |
473 |
|
|
$ |
1,805 |
|
Effects of Foreign Currency Translation
The Company's foreign subsidiaries transact business and report financial results in their respective local currencies. These results are translated into
|
($ in millions) |
|
Three Months Ended |
|
|
Change |
|
|
Change |
|
|
Twelve Months Ended |
|
|
Change |
|
|
Change |
|
||||||||||||||
|
|
|
2025 |
|
|
2024 |
|
|
|
|
|
|
|
|
2025 |
|
|
2024 |
|
|
|
|
|
|
|
||||||||
|
|
|
$ |
553.9 |
|
|
$ |
525.6 |
|
|
$ |
28.3 |
|
|
$ |
16.1 |
|
|
$ |
2,332.1 |
|
|
$ |
2,180.3 |
|
|
$ |
151.8 |
|
|
$ |
4.6 |
|
|
Gross Profit |
|
|
51.5 |
|
|
|
56.7 |
|
|
$ |
(5.2) |
|
|
|
1.5 |
|
|
|
269.9 |
|
|
|
272.2 |
|
|
$ |
(2.3) |
|
|
|
(0.4) |
|
|
Operating Income |
|
|
10.5 |
|
|
|
7.7 |
|
|
$ |
2.8 |
|
|
|
0.7 |
|
|
|
78.5 |
|
|
|
70.5 |
|
|
$ |
8.0 |
|
|
|
(0.8) |
|
|
Pretax Income |
|
|
4.9 |
|
|
|
2.5 |
|
|
$ |
2.4 |
|
|
|
0.5 |
|
|
|
59.9 |
|
|
|
60.4 |
|
|
$ |
(0.5) |
|
|
|
(1.1) |
|
|
|
|
Corporate Expenses |
||||||||||||||||||||||
|
|
|
|
||||||||||||||||||||||
|
|
|
Three Months Ended |
|
|
Twelve Months Ended |
|
||||||||||||||||||
|
($ in thousands) |
|
2025 |
|
|
2024 |
|
|
% |
|
|
2025 |
|
|
2024 |
|
|
% |
|
||||||
|
Total Corporate Expenses |
|
$ |
8,065 |
|
|
$ |
17,468 |
|
|
|
(54) |
% |
|
$ |
57,714 |
|
|
$ |
76,669 |
|
|
|
(25) |
% |
|
Less: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||||
|
Deferred Compensation Expense |
|
$ |
549 |
|
|
$ |
(574) |
|
|
|
(196) |
% |
|
$ |
2,155 |
|
|
$ |
2,155 |
|
|
|
(—) |
% |
|
Environmental Remediation |
|
$ |
87 |
|
|
$ |
225 |
|
|
|
(61) |
% |
|
$ |
1,245 |
|
|
$ |
2,540 |
|
|
|
(51) |
% |
|
Goodwill Impairment |
|
$ |
6,245 |
|
|
$ |
- |
|
|
NM |
|
|
$ |
6,245 |
|
|
$ |
- |
|
|
NM |
|
||
|
Gain on Sale of Assets |
|
$ |
(15,895) |
|
|
$ |
- |
|
|
NM |
|
|
$ |
(15,895) |
|
|
$ |
- |
|
|
NM |
|
||
|
Adjusted Corporate Expenses |
|
$ |
17,079 |
|
|
$ |
17,817 |
|
|
|
(4) |
% |
|
$ |
63,964 |
|
|
$ |
71,974 |
|
|
|
(11) |
% |
Adjusted Corporate expenses decreased
Table V
|
Consolidated Balance Sheets
|
||||||||
|
|
||||||||
|
|
|
|
|
|
|
|
||
|
ASSETS |
|
|
|
|
|
|
||
|
Current Assets |
|
$ |
858,959 |
|
|
$ |
810,429 |
|
|
Property, |
|
|
1,219,627 |
|
|
|
1,198,454 |
|
|
Other Assets |
|
|
279,116 |
|
|
|
295,765 |
|
|
Total Assets |
|
$ |
2,357,702 |
|
|
$ |
2,304,648 |
|
|
LIABILITIES AND STOCKHOLDERS' EQUITY |
|
|
|
|
|
|
||
|
Current Liabilities |
|
$ |
666,494 |
|
|
$ |
669,034 |
|
|
Deferred Income Taxes |
|
|
11,450 |
|
|
|
9,612 |
|
|
Long-term Debt |
|
|
340,975 |
|
|
|
332,632 |
|
|
Other Non-current Liabilities |
|
|
94,773 |
|
|
|
123,436 |
|
|
Total Stepan Company Stockholders' Equity |
|
|
1,244,010 |
|
|
|
1,169,934 |
|
|
Total Liabilities and Stockholders' Equity |
|
$ |
2,357,702 |
|
|
$ |
2,304,648 |
|
Selected Balance Sheet Information
The Company's total debt decreased by
|
($ in millions) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||
|
Net Debt |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||
|
Total Debt |
$ |
626.7 |
|
|
$ |
655.5 |
|
|
$ |
658.0 |
|
|
$ |
659.3 |
|
|
$ |
625.4 |
|
|
Cash |
|
132.7 |
|
|
|
118.5 |
|
|
|
88.9 |
|
|
|
107.5 |
|
|
|
99.7 |
|
|
Net Debt |
$ |
494.0 |
|
|
$ |
537.0 |
|
|
$ |
569.1 |
|
|
$ |
551.8 |
|
|
$ |
525.7 |
|
|
Equity |
|
1,244.0 |
|
|
|
1,246.8 |
|
|
|
1,241.7 |
|
|
|
1,200.5 |
|
|
|
1,169.9 |
|
|
Net Debt + Equity |
$ |
1,738.0 |
|
|
$ |
1,783.8 |
|
|
$ |
1,810.8 |
|
|
$ |
1,752.3 |
|
|
$ |
1,695.6 |
|
|
Net Debt / (Net Debt + Equity) |
|
28 |
% |
|
|
30 |
% |
|
|
31 |
% |
|
|
31 |
% |
|
|
31 |
% |
The major working capital components were:
|
($ in millions) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||
|
Net Receivables |
$ |
388.0 |
|
|
$ |
436.1 |
|
|
$ |
442.2 |
|
|
$ |
436.5 |
|
|
$ |
388.0 |
|
|
Inventories |
|
298.8 |
|
|
|
324.3 |
|
|
|
329.5 |
|
|
|
309.3 |
|
|
|
288.7 |
|
|
Accounts Payable |
|
(261.7) |
|
|
|
(289.4) |
|
|
|
(281.8) |
|
|
|
(298.1) |
|
|
|
(258.8) |
|
|
|
$ |
425.1 |
|
|
$ |
471.0 |
|
|
$ |
489.9 |
|
|
$ |
447.7 |
|
|
$ |
417.9 |
|
Table VI
Reconciliations of Non-GAAP EBITDA and Adjusted EBITDA
Management uses the non-GAAP EBITDA and adjusted EBITDA metrics to evaluate the Company's operating performance. Management excludes the items listed in the table below because they are non-operational items. Refer to the Income Statement on Table I for a bridge between Operating Income and Net Income.
|
|
|
Three Months Ended |
||||||||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||
|
($ in millions) |
|
Surfactants |
|
|
Polymers |
|
|
Specialty |
|
|
Unallocated |
|
|
Consolidated |
|
|||||
|
Operating Income |
|
$ |
9.4 |
|
|
$ |
4.0 |
|
|
$ |
5.2 |
|
|
$ |
(8.1) |
|
|
$ |
10.5 |
|
|
Depreciation and Amortization |
|
|
22.7 |
|
|
|
8.4 |
|
|
|
1.5 |
|
|
|
0.1 |
|
|
|
32.7 |
|
|
Other, Net Income |
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
0.1 |
|
|
|
0.1 |
|
|
EBITDA |
|
|
|
|
|
|
|
|
|
|
|
|
|
$ |
43.3 |
|
||||
|
Deferred Compensation |
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
0.1 |
|
|
|
0.1 |
|
|
Environmental Remediation |
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
0.1 |
|
|
|
0.1 |
|
|
Goodwill Impairment |
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
6.2 |
|
|
|
6.2 |
|
|
Gain on Sale of Assets |
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
(15.9) |
|
|
|
(15.9) |
|
|
Adjusted EBITDA |
|
$ |
32.1 |
|
|
$ |
12.4 |
|
|
$ |
6.7 |
|
|
$ |
(17.4) |
|
|
$ |
33.8 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||
|
|
|
Three Months Ended |
|
|||||||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||
|
($ in millions) |
|
Surfactants |
|
|
Polymers |
|
|
Specialty |
|
|
Unallocated |
|
|
Consolidated |
|
|||||
|
Operating Income |
|
$ |
16.2 |
|
|
$ |
3.4 |
|
|
$ |
5.6 |
|
|
$ |
(17.5) |
|
|
$ |
7.7 |
|
|
Depreciation and Amortization |
|
|
18.5 |
|
|
|
8.0 |
|
|
|
1.5 |
|
|
|
0.5 |
|
|
|
28.5 |
|
|
Other, Net Income |
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
(0.4) |
|
|
|
(0.4) |
|
|
EBITDA |
|
|
|
|
|
|
|
|
|
|
|
|
|
$ |
35.8 |
|
||||
|
Deferred Compensation |
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
(1.0) |
|
|
|
(1.0) |
|
|
Environmental Remediation |
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
0.2 |
|
|
|
0.2 |
|
|
Adjusted EBITDA |
|
$ |
34.7 |
|
|
$ |
11.4 |
|
|
$ |
7.1 |
|
|
$ |
(18.2) |
|
|
$ |
35.0 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Twelve Months Ended |
|
|||||||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||
|
($ in millions) |
|
Surfactants |
|
|
Polymers |
|
|
Specialty |
|
|
Unallocated |
|
|
Consolidated |
|
|||||
|
Operating Income |
|
$ |
67.4 |
|
|
$ |
43.3 |
|
|
$ |
25.6 |
|
|
$ |
(57.8) |
|
|
$ |
78.5 |
|
|
Depreciation and Amortization |
|
|
85.6 |
|
|
|
33.1 |
|
|
|
5.9 |
|
|
|
1.4 |
|
|
|
126.0 |
|
|
Other, Net Income |
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
3.5 |
|
|
|
3.5 |
|
|
EBITDA |
|
|
|
|
|
|
|
|
|
|
|
|
|
$ |
208.0 |
|
||||
|
Deferred Compensation |
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
(0.6) |
|
|
|
(0.6) |
|
|
Environmental Remediation |
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
1.2 |
|
|
|
1.2 |
|
|
Goodwill Impairment |
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
6.2 |
|
|
|
6.2 |
|
|
Gain on Sale of Assets |
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
(15.9) |
|
|
|
(15.9) |
|
|
Adjusted EBITDA |
|
$ |
153.0 |
|
|
$ |
76.4 |
|
|
$ |
31.5 |
|
|
$ |
(62.0) |
|
|
$ |
198.9 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||
|
|
|
Twelve Months Ended |
|
|||||||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||
|
($ in millions) |
|
Surfactants |
|
|
Polymers |
|
|
Specialty |
|
|
Unallocated |
|
|
Consolidated |
|
|||||
|
Operating Income |
|
$ |
85.6 |
|
|
$ |
40.6 |
|
|
$ |
20.9 |
|
|
$ |
(76.6) |
|
|
$ |
70.5 |
|
|
Depreciation and Amortization |
|
|
72.0 |
|
|
|
32.4 |
|
|
|
6.0 |
|
|
|
1.9 |
|
|
|
112.3 |
|
|
Other, Net Income |
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
4.1 |
|
|
|
4.1 |
|
|
EBITDA |
|
|
|
|
|
|
|
|
|
|
|
|
|
$ |
186.9 |
|
||||
|
Deferred Compensation |
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
(2.4) |
|
|
|
(2.4) |
|
|
Environmental Remediation |
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
2.5 |
|
|
|
2.5 |
|
|
Adjusted EBITDA |
|
$ |
157.6 |
|
|
$ |
73.0 |
|
|
$ |
26.9 |
|
|
$ |
(70.5) |
|
|
$ |
187.0 |
|
View original content to download multimedia:https://www.prnewswire.com/news-releases/stepan-reports-fourth-quarter-and-full-year-2025-results-302694000.html
SOURCE